

Consolidated Financial Statements and Uniform Guidance Reports

Year Ended June 30, 2019

(With Independent Auditors' Report Thereon)

Table of Contents

| | Page(s) |
|--|---------|
| Independent Auditors' Report | 1–2 |
| Consolidated Financial Statements: | |
| Consolidated Balance Sheet | 3 |
| Consolidated Statement of Activities | 4 |
| Consolidated Statement of Cash Flows | 5 |
| Notes to Consolidated Financial Statements | 6–31 |
| Schedule of Expenditures of Federal Awards | 32–34 |
| Notes to Schedule of Expenditures of Federal Awards | 35–36 |
| Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards | 37–38 |
| Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance | 39–41 |
| Schedule of Findings and Questioned Costs | 42–45 |



KPMG LLP Suite 1900 440 Monticello Avenue Norfolk, VA 23510

Independent Auditors' Report

The Board of Visitors
Eastern Virginia Medical School:

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Eastern Virginia Medical School and Affiliated Organization (EVMS), which comprise the consolidated balance sheet as of June 30, 2019, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to EVMS' preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of EVMS' internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Eastern Virginia Medical School and Affiliated Organization as of June 30, 2019, results of activities, and their cash flows for the year then ended, in accordance with U.S. generally accepted accounting principles.



Report on Summarized Comparative Information

We have previously audited EVMS' 2018 consolidated financial statements, and we expressed an unmodified audit opinion on those audited consolidated financial statements in our report dated October 29, 2018. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2018 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

Emphasis of Matter

As discussed in note 2(t) to the consolidated financial statements, EVMS adopted Financial Accounting Standards Board Accounting Standards Update No. 2016-14, *Not-for-Profit Entities (Topic 958): Presentation of Financial Statements of Not-for-Profit Entities*, during the year ended June 30, 2019. Our opinion is not modified with respect to this matter.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 31, 2019 on our consideration of EVMS' internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of EVMS' internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering EVMS' internal control over financial reporting and compliance.

KPMG LLP

Norfolk, Virginia October 31, 2019

Consolidated Balance Sheet

June 30, 2019 (With summarized financial information as of June 30, 2018)

| Assets | _ | 2019 | 2018 |
|---|-------------|---|--|
| Current assets: Cash and cash equivalents Restricted cash and investments Operating investments Accounts receivable, net Accounts receivable from affiliate Current portion of notes receivable from students Prepaid expenses and other current assets Total current assets | \$ - | 77,945,889 6,780,183 21,113,202 24,539,434 382,991 730,800 2,504,232 133,996,731 | 43,444,317 7,027,241 16,577,386 23,611,418 771,962 847,800 2,482,065 94,762,189 |
| Property, plant, and equipment, net | | 146,705,843 | 125,455,913 |
| Other long-term assets: Operating investments Notes receivable from students Interest in net assets of affiliate Other long-term assets | - | 16,063,700 3,746,182 128,081,411 3,892,971 | 19,554,649 4,373,064 105,900,342 3,790,349 |
| Total other long-term assets | - | 151,784,264 | 133,618,404 |
| Total assets | \$ <u>_</u> | 432,486,838 | 353,836,506 |
| Liabilities and Net Assets | | | |
| Liabilities: Current liabilities: Current portion of long-term debt Accounts payable – trade Accrued compensation Deferred income | \$ | 1,945,000 11,745,932 8,109,769 5,647,702 | 4,500,000 8,890,151 5,445,571 5,826,240 |
| Accrued expenses and other current liabilities | | 11,017,911 | 8,988,158 |
| Total current liabilities | _ | 38,466,314 | 33,650,120 |
| Long-term debt, excluding current portion and net of bond issuance costs | | 34,364,036 | 33,536,921 |
| Other long-term liabilities: Grant deposits Refundable federal student loans Assets held for affiliate Other long-term liabilities Total other long-term liabilities Total liabilities | - | 3,019,292 4,030,610 928,199 3,986,134 11,964,235 84,794,585 | 2,633,439 4,417,445 910,855 2,769,365 10,731,104 77,918,145 |
| Net assets: Net assets without donor restrictions Operating EVMS reserves Department reserves Net investment in plant Parking facility reserves | _ | 8,377,770 65,582,782 52,774,577 28,510,973 301,413 | 8,130,983 42,938,756 49,452,932 23,064,945 163,210 |
| Total net assets without donor restrictions | _ | 155,547,515 | 123,750,826 |
| Net assets with donor restrictions Revolving student loans Program restricted Net investment in plant Interest in net assets of affiliate | _ | 1,686,376 718,497 61,658,454 128,081,411 | 1,715,685 686,970 43,864,538 105,900,342 |
| Total net assets with donor restrictions | _ | 192,144,738 | 152,167,535 |
| Total net assets | _ | 347,692,253 | 275,918,361 |
| Commitments and contingencies | | | |
| Total liabilities and net assets | \$ | 432,486,838 | 353,836,506 |

See accompanying notes to consolidated financial statements.

Consolidated Statement of Activities

Year ended June 30, 2019 (With summarized financial information for the year ended June 30, 2018)

| | | Net assets without donor restrictions | Net assets with donor restrictions | Total | 2018 total |
|---|----|---------------------------------------|--|-------------|---------------|
| Operating revenues and support: | | | | | |
| Tuition and fees, net | \$ | 46,379,664 | _ | 46,379,664 | 44,317,668 |
| State appropriations | * | 29,277,322 | 20,559,541 | 49,836,863 | 25,787,561 |
| Municipal subsidies | | 1,386,108 | _ | 1,386,108 | 1,382,004 |
| Federal grants and contracts | | 23,002,741 | _ | 23,002,741 | 24,872,597 |
| State grants and contracts | | 930,891 | _ | 930,891 | 1,069,240 |
| Private grants, contracts, and gifts | | 3,734,201 | _ | 3,734,201 | 3,674,473 |
| EVMS Foundation endowment income and gifts | | 6,843,199 | _ | 6,843,199 | 6,581,038 |
| Patient care services, net | | 57,064,595 | _ | 57,064,595 | 55,749,885 |
| Contractual services of graduate school residents | | 37,010,340 | _ | 37,010,340 | 35,468,208 |
| Contractual services | | 94,956,673 | _ | 94,956,673 | 35,352,026 |
| Sales and services of auxiliary enterprises | | 7,106,272 | _ | 7,106,272 | 6,713,644 |
| Other sources | | 6,278,265 | 706,158 | 6,984,423 | 5,842,573 |
| Interest and investment income | | 1,221,794 | 12,657 | 1,234,451 | 1,256,712 |
| Released from restriction | | 3,482,222 | (3,482,222) | | |
| Total operating revenues and support | | 318,674,287 | 17,796,134 | 336,470,421 | 248,067,629 |
| Operating expenses: | | | | | |
| Undergraduate instruction | | 99,198,688 | _ | 99,198,688 | 49,955,215 |
| Graduate instruction | | 29,338,809 | _ | 29,338,809 | 28,139,580 |
| Research | | 25,557,860 | _ | 25,557,860 | 26,707,390 |
| Patient services | | 70,730,340 | _ | 70,730,340 | 67,474,080 |
| Academic support | | 9,964,639 | _ | 9,964,639 | 8,885,361 |
| Institutional support | | 23,390,257 | _ | 23,390,257 | 20,272,745 |
| Auxiliary services | | 21,235,549 | _ | 21,235,549 | 20,557,546 |
| Patient services support | | 7,763,569 | | 7,763,569 | 7,926,780 |
| Total operating expenses | | 287,179,711 | | 287,179,711 | 229,918,697 |
| Changes in net assets from operations | | 31,494,576 | 17,796,134 | 49,290,710 | 18,148,932 |
| Nonoperating items: | | | | | |
| Unrealized gains (losses) from investments, net | | 1,529,794 | _ | 1,529,794 | (919,578) |
| Change in interest of net assets of affiliate | | · · · · — | 22,181,069 | 22,181,069 | 7,305,013 |
| Change in fair value of interest rate swaps | | (1,227,681) | <u> </u> | (1,227,681) | 1,145,990 |
| Changes in net assets | | 31,796,689 | 39,977,203 | 71,773,892 | 25,680,357 |
| Net assets at beginning of year | | 123,750,826 | 152,167,535 | 275,918,361 | 250,238,004 |
| Net assets at end of year | \$ | 155,547,515 | 192,144,738 | 347,692,253 | 275,918,361 |

See accompanying notes to consolidated financial statements.

Consolidated Statement of Cash Flows

Year ended June 30, 2019 (With summarized financial information for the year ended June 30, 2018)

| | _ | 2019 | 2018 |
|--|----------|----------------|--------------|
| Cash flows from operating activities: | | | |
| Changes in net assets | \$ | 71,773,892 | 25,680,357 |
| Adjustments to reconcile changes in net assets to net cash provided by operating activities: | • | , -, | -,, |
| Depreciation and amortization | | 9,386,553 | 10,248,539 |
| Change in fair value of interest rate swaps | | 1,227,681 | (1,145,990) |
| Net realized and unrealized (gains) losses on investments | | (1,564,627) | 786,056 |
| Change in interest of net assets of affiliate | | (22,181,069) | (7,305,013) |
| Net (gain) loss on sale of property, plant, and equipment | | 23,474 | (230,211) |
| Provision for bad debts | | 16,405,457 | 14,221,057 |
| Amortization of bond issuance costs | | 22,102 | 26,369 |
| State appropriation for property, plant, and equipment | | (23,786,087) | (1,369,021) |
| Changes in: | | (20). 00,00. / | (1,000,021) |
| Accounts receivable, net | | (17,149,309) | (13,089,928) |
| Accounts receivable from affiliate | | 388,971 | 862,635 |
| Prepaid expenses and other current assets | | (22,167) | (396,901) |
| Other long-term assets | | (2,400) | (2,396) |
| Accounts payable – trade | | 2,855,781 | 1,176,574 |
| Accrued compensation | | 2,664,198 | (1,758,224) |
| Deferred income | | (178,538) | 989,587 |
| Accrued expenses and other current liabilities | | 2,029,753 | (226,311) |
| Grant deposits | | 385,853 | (726,083) |
| Assets held for affiliate | | 17,344 | 19,449 |
| Other long-term liabilities | | 1,216,769 | 559,120 |
| Other long-term habilities | = | 1,210,709 | 339,120 |
| Net cash provided by operating activities | - | 43,513,631 | 28,319,665 |
| Cash flows from investing activities: | | | |
| Purchases of restricted cash and investments | | (7,992,211) | (7,846,004) |
| Proceeds from sales and maturities of restricted cash and investments | | 8,239,269 | 6,327,216 |
| Purchases of operating investments | | (22,672,422) | (1,125,678) |
| Proceeds from sales and maturities of operating investments | | 23,192,182 | 5,712,055 |
| Purchases of property, plant, and equipment | | (30,728,847) | (14,239,649) |
| Proceeds from sale of property, plant, and equipment | | 68,890 | 379,805 |
| Disbursements for notes receivable from students | | (429,133) | (310,600) |
| Collections of notes receivable from students | | 988,851 | 1,173,250 |
| Change in cash surrender value of life insurance | _ | (100,222) | (123,348) |
| Net cash used in investing activities | _ | (29,433,643) | (10,052,953) |
| Cash flows from financing activities: | | | |
| State appropriation for property, plant, and equipment | | 23,786,087 | 1,369,021 |
| Proceeds from long-term borrowings | | 2,340,582 | 1,505,021 |
| Payments for bond issuance costs | | (68,250) | |
| Principal payments on bonds | | (5,250,000) | (4,100,000) |
| Refundable federal student loans | | (386,835) | (1,182,326) |
| Net cash provided by (used in) financing activities | - | 20,421,584 | (3,913,305) |
| Net increase in cash and cash equivalents | - | 34,501,572 | 14,353,407 |
| Cash and cash equivalents at beginning of year | | 43,444,317 | 29,090,910 |
| | <u>.</u> | | |
| Cash and cash equivalents at end of year | \$ | 77,945,889 | 43,444,317 |
| Supplemental disclosures of cash flow information: | | | |
| Cash paid for interest, net of amounts capitalized | \$ | 1,161,668 | 1,325,134 |
| Purchases of property, plant, and equipment included in accounts payable – trade | | 3,771,722 | 589,914 |

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

(1) EVMS and Affiliated Organization

The Eastern Virginia Medical School (EVMS or the School) was created in 1964 by enabling legislation of the General Assembly of Virginia to identify, document, and evaluate needs, problems, and resources relating to health and medical care within its service area and to plan, develop, and implement programs to meet such needs on both an immediate and long-range basis. EVMS may plan, design, construct, remove, enlarge, equip, maintain, and operate medical educational institutions and medical and paramedical facilities, together with related and supporting facilities, and do all things necessary and convenient to carry out any of its purposes. EVMS' powers also include the right of eminent domain within the City of Norfolk and the authorization to borrow funds and issue bonds. EVMS has been classified as an organization described in Section 501(c)(3) of the Internal Revenue Code (IRC). As such, EVMS is exempt from federal and state income taxation, and contributions to it are tax deductible.

EVMS Medical Group (EVMS MG) is a nonmember organization incorporated under the Virginia Non Stock Corporation Act. Prior to July 1, 1989, EVMS MG was an operating division of EVMS. Effective July 1, 1989, EVMS MG began operations as a not-for-profit foundation through the approval of EVMS MG's Articles of Incorporation and Bylaws by the EVMS Board of Visitors. EVMS MG bylaws cannot be altered or amended without the approval of the EVMS Board of Visitors. EVMS MG has been classified as an organization described in Section 501(c)(3) of the IRC and is exempt from federal and state income taxation. The accounts of EVMS MG are included in the accompanying consolidated financial statements.

The Eastern Virginia Medical School Foundation (EVMS Foundation) is a nonprofit organization established to provide financial support to EVMS. The EVMS Foundation qualifies as a charitable foundation and is exempt from federal and state income taxation under Section 501(c)(3) of the IRC. As such, contributions to it are tax deductible. The accounts of EVMS Foundation are not included in the consolidated financial statements of EVMS. Amounts received from the EVMS Foundation are reported as endowment income in EVMS' consolidated financial statements. EVMS' beneficial interest in the net assets of EVMS Foundation of \$128,081,411 and \$105,900,342 as of June 30, 2019 and 2018, respectively, is presented as interest in net assets of affiliate within net assets with donor restrictions. Once the funds have met their donor-imposed restrictions and are remitted to EVMS, they are reported as net assets without donor restrictions. Changes in the interest of the net assets of EVMS Foundation are included in nonoperating items on the accompanying consolidated statement of activities. During the years ended December 31, 2019 and 2018, income from the EVMS Foundation of \$6,843,199 and \$6,581,038, respectively, is presented in operating revenues and support on the accompanying consolidated statement of activities.

EVMS has defined its mission as a community-based academic institution dedicated to medical and health education, research, and patient care.

(a) Education

Undergraduate Education – Opened in 1973, EVMS offers a Doctor of Medicine (M.D.) degree. In 2004, the Association of American Medical Colleges' Liaison Committee on Medical Education awarded EVMS continued full accreditation of the educational program leading to the M.D. degree.

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

In 2009, the Southern Association of Colleges and Schools awarded EVMS a continuation of accreditation for a 10-year period.

EVMS also offers several health professions programs, including master's degrees in art therapy, public health, physician assistant, clinical embryology, surgical assistant, biotechnology and biomedical sciences, and doctoral degrees in clinical psychology and biomedical sciences in conjunction with other local universities.

Graduate Medical Education (GME) – Founded in 1974, GME offers residency and fellowship programs at numerous healthcare facilities in EVMS' service area. Programs are accredited by the Accreditation Council of Graduate Medical Education or the American Psychological Association or are approved by specialty boards.

(b) Research

EVMS conducts numerous research projects in various areas, including proteomics, cancer, reproductive medicine, systemic diseases, and infectious diseases. EVMS-sponsored research is supported by various federal and state agencies, pharmaceutical companies, and private foundations.

(c) Patient Care

Clinical care is provided through the following affiliates:

EVMS MG – EVMS MG was formed exclusively for charitable, scientific, and educational purposes and to further the mission and goals of EVMS. EVMS MG is organized and shall at all times operate to fulfill its corporate purpose by supporting clinical practice and research in conjunction with providing faculty the opportunity to teach in a physician group practice setting within the academic environment of EVMS. EVMS MG also provides education and training to EVMS students and residents. EVMS MG incorporates the professional practice units of the EVMS faculty in all departments except pediatrics. The practice units are staffed solely by faculty members of EVMS who provide professional patient care at EVMS facilities or through agreements with other area hospitals.

EVMS Pediatrics, formerly Pediatric Faculty Associates, Inc. (PFA) – PFA was established through an affiliation agreement between EVMS, Children's Hospital of the King's Daughters (CHKD), and Children's Health System, Inc. During fiscal year 1998, PFA underwent significant organizational and structural changes. A majority of the full-time faculty members in the pediatric specialties established a for-profit professional limited liability company, Children's Specialty Group, PLLC (CSG). On June 30, 2008, the PFA corporate status was dissolved. All assets and liabilities were transferred to EVMS and reported as EVMS Pediatrics.

EVMS Pediatrics, along with CSG, incorporates the professional practice units of the EVMS faculty in the pediatric specialties. They provide professional patient care at EVMS or CHKD facilities or through agreements with other area hospitals.

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation and Consolidation

EVMS' consolidated financial statements have been prepared on the accrual basis of accounting. All intercompany balances and transactions have been eliminated in consolidation. These consolidated financial statements have been prepared to focus on EVMS as a whole and to present balances and transactions according to the existence or absence of donor-imposed restrictions. Resources are classified based on the existence or absence of donor-imposed restrictions and are segregated into two net asset groups as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations. Net assets without donor restrictions are those net assets that are the result of revenues and income minus expenses and are grouped by operating, EVMS reserves, department reserves, net investment in plant, and the parking facility. Designated net assets are reported on the balance sheet as EVMS reserves and department reserves and represent net assets that are subject to self-imposed limits by action of management, as delegated by the governing board.

Net assets with donor restrictions – Net assets subject to donor-imposed stipulations that may or will be met by actions of EVMS and/or the passage of time. The interest in net assets of affiliate is restricted by time, while the remaining net assets with donor restrictions are restricted by purpose.

Revenues are reported as increases in net assets without donor restrictions unless use of the related assets is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions or net assets with donor restrictions. Expirations of temporary restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restriction in the consolidated statement of activities. Contributions, including unconditional promises to give, are recognized as revenue in the period received. Contributions for acquisition or construction of plant facilities are released from restrictions in the period in which the assets are placed in service, unless the donor specifies the asset must be used for a specified period of time. Contributions that impose restrictions that are met in the same fiscal year they are received are reported as increases in net assets without donor restrictions.

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

Designated net assets at June 30 are summarized as follows:

| | 2019 | 2018 |
|---|-------------|------------|
| EVMS reserves: | | |
| President and institutional development \$ | 51,362,074 | 27,199,217 |
| Faculty development | 6,441,006 | 2,043,995 |
| Internal research | 958,332 | 901,243 |
| Strategic planning | 6,094,676 | 10,651,593 |
| Academic student information | 726,694 | 2,142,708 |
| Total EVMS reserves | 65,582,782 | 42,938,756 |
| Department reserves: | | |
| Insurance and legal reserves | 11,446,929 | 11,489,752 |
| Faculty development | 9,350,538 | 10,145,552 |
| Internal research | 7,896,591 | 4,405,804 |
| President and institutional development | 4,686,495 | 2,352,075 |
| Chairman's fund | 3,748,526 | 4,196,602 |
| Facilities and equipment | 3,598,088 | 3,147,451 |
| Strategic planning | 1,549,778 | 1,241,829 |
| Resident education | 1,508,383 | 1,511,045 |
| Student fees | 1,497,054 | 1,301,320 |
| Other | 2,392,001 | 1,550,093 |
| Physician supplemental payment program – EVMS MG | 2,040,450 | 2,460,983 |
| Unallocated nonsalary physician compensation – EVMS MG | 1,656,657 | 4,249,953 |
| Operating reserve – EVMS MG | 1,403,087 | 1,400,474 |
| Total department reserves | 52,774,577 | 49,452,933 |
| Total designated net assets without donor restrictions \$ | 118,357,359 | 92,391,689 |

The consolidated financial statements include certain prior year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with U.S. generally accepted accounting principles (GAAP). Accordingly, such information should be read in conjunction with EVMS' consolidated financial statements as of and for the year ended June 30, 2018, from which the summarized information was derived. In addition, certain reclassifications have been made to the prior year amounts in order to conform to the current year presentation.

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

(b) Cash and Cash Equivalents

EVMS considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents for consolidated financial statement presentation, except for those short-term investments managed by EVMS' investment managers as part of their long-term investment portfolio. Cash equivalents consist primarily of temporary investments in bank repurchase agreements, money market funds, and cash reserve funds.

(c) Restricted Cash and Investments

Restricted cash and investments represents funds that have been externally restricted or internally designated for a specific purpose and are reported on the consolidated balance sheet at fair value.

(d) Investments

Investments are classified as trading and are reported on the consolidated balance sheet at fair value. Net realized gains and losses on investments are reflected in operating revenues and support in the accompanying consolidated statement of activities. Net unrealized gains and losses on investments are reflected in nonoperating items in the accompanying consolidated statement of activities. The current year gains and losses on investments have been recognized in the accompanying consolidated statement of activities as increases or decreases in net assets without donor restrictions, unless their use is restricted by explicit donor stipulations.

(e) Patient Accounts Receivable

Patient receivables are recorded net of allowances for contractual adjustments and uncollectible receivables. The allowance for doubtful accounts is EVMS MG's best estimate of the amount of probable credit losses in its existing receivables. EVMS MG determines the allowance based on historical write-off experience and identifies trends for each of its major payor sources of revenue to estimate the appropriate allowance for doubtful accounts. Management regularly reviews data about these major payor sources of revenue in evaluating the sufficiency of the allowance for doubtful accounts. For receivables associated with services provided to patients who have third-party coverage, EVMS MG analyzes contractually due amounts and provides an allowance for doubtful accounts and provision for bad debts, if necessary. For receivables associated to self-pay patients, EVMS MG records a provision for bad debts in the period of service on the basis of its past experience, which indicates that many patients are unable or unwilling to pay a portion of their bill for which they are financially responsible. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. EVMS MG does not have any off-balance-sheet credit exposure related to its customers.

(f) Property, Plant, and Equipment

Property, plant, and equipment are stated at cost or at estimated fair value at date of gift if acquired by gift. Depreciation is computed using the straight-line method over the estimated useful lives of the property, plant, and equipment.

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

The estimated useful lives are as follows:

Land improvements 5–20 years
Buildings and improvements 5–40 years
Equipment 3–20 years

(g) Other Long-Term Assets

Other long-term assets in the accompanying consolidated balance sheet are primarily comprised of cash surrender value of life insurance policies held by EVMS MG.

EVMS MG is the owner of two insurance policies for current and retired faculty of EVMS, where EVMS MG is the beneficiary. These policies are recorded at their net cash surrender values, as reported by the issuing insurance company, whose Standard & Poor's financial strength rating is AA+. The net cash surrender values totaled \$3,763,913 and \$3,663,691 as of June 30, 2019 and 2018, respectively.

The cash surrender value of life insurance is valued under Level 2 of the fair value hierarchy at June 30, 2019 and 2018. The cash surrender value of life insurance was determined by the underwriting insurance company's valuation models, which take into account the passage of time, mortality tables, interest rates, cash values for paid-up additions, and dividend accumulations. The cash surrender value represents the guaranteed value EVMS MG would receive upon surrender of these policies held on key employees as of June 30, 2019.

(h) Refundable Federal Student Loans

Funds provided by the U.S. government under the Federal Perkins and Health Professions Student Loan Programs are loaned to qualified students and may be reloaned after collections. These funds are ultimately refundable to the government and are reported as liabilities in the accompanying consolidated balance sheet. Due to the dissolution of the Perkins Loan program, no new Perkins Loans were disbursed during the year ended June 30, 2019.

(i) Tuition and Fees, Net

Student tuition and fees are recorded as revenue during the year that the related academic services are rendered. Student tuition and fees received in advance of services to be rendered are recorded as deferred income. Student aid provided by EVMS for tuition and fees is reflected as a reduction of gross tuition and fee revenue.

(j) Patient Care Services, Net

EVMS MG has agreements with third-party payors that provide for payments to EVMS MG at amounts different from its established rates. Payment arrangements include prospectively determines rates, reimbursement costs, discounted charges, and per diem payments. Patient care services revenue is reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered. Reimbursements from third-party payors are subject to examination by the agencies administering the programs from compliance with procedures and documentation standards.

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

EVMS MG has agreements with various Health Maintenance Organizations (HMOs) to provide medical services to subscribing participants. The HMOs generally make fee-for-service payments to EVMS MG for certain covered services based upon discounted fee schedules.

(k) Charity Care

EVMS MG provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. Because EVMS MG does not pursue collection of amounts determined to qualify as charity care, they are not reported as revenue in the accompanying consolidated statement of activities.

EVMS MG maintains detailed records to identify and monitor the level of charity care it provides to its patients. These records include the amount of charges foregone and estimated direct and indirect costs incurred for services furnished under its charity care policy. Costs incurred are estimated based on the ratio of total operating expenses to gross charges applied to charity care charges. The following information measures the level of charity care provided during the years ended June 30:

| | 2019 | 2018 |
|--|-----------------|-----------|
| Charges foregone, based on established rates | \$ 1,041,775 | 1,371,152 |
| Estimated costs incurred | 566,755 | 791,149 |

(I) Sponsored Grants and Contracts

Revenues under grants, contracts, and similar agreements with sponsoring organizations are recognized as expenses are incurred for agreement purposes. The revenues include recoveries of indirect costs and fringe benefits, which are generally determined as a negotiated or agreed-upon percentage of direct costs with certain exclusions.

(m) Derivative Instruments

EVMS utilizes derivative financial instruments to reduce its exposure to cash flow risks from changes in interest rates, specifically, variable interest rates. EVMS is exposed to credit losses in the event of nonperformance by the counterparty to the interest rate swap; however, the counterparty is a major financial institution, and the risk of loss due to nonperformance is considered remote. Interest rate differentials paid or received on the swap are recognized as adjustments to expense in the period earned or incurred. Interest rate swaps are recorded at fair value and reflected as assets or liabilities in the accompanying consolidated balance sheet. Changes in the fair value of interest rate swaps are reflected as nonoperating items in the accompanying consolidated statement of activities.

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

(n) Concentration of Credit Risk

Financial instruments, which potentially subject EVMS and its affiliated organization to concentration of credit risk, consist principally of cash, investments, patient receivables, and student notes receivable.

EVMS and its affiliated organization place unrestricted cash and temporary overnight investments with high credit quality financial institutions. EVMS and the EVMS Foundation's endowment assets are allocated between several established, reputable asset management firms and, according to their investment policy, are invested in investment-grade instruments. The asset management firms are independent of the funds' trustees, who review their performance on a periodic basis.

(o) Long-Lived Assets

Long-lived assets, such as property, plant, and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, EVMS first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. Fair value is determined through various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, as considered necessary. There was no impairment recorded in fiscal year 2019 or 2018.

(p) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful life of fixed assets, allowance for doubtful accounts, the valuation of derivatives, and investments.

(q) Income Taxes

EVMS is exempt from income taxes under Section 501(a) of the IRC as an organization described in Section 501(c)(3). Accordingly, no provision for income taxes is made in the consolidated financial statements. As of June 30, 2019 and 2018, there were no uncertain tax positions.

(r) Release from Restriction

EVMS receives restricted revenue from the Commonwealth of Virginia to fund the construction and purchase of certain real property during the years ended June 30, 2009–2019. As a part of the agreement, EVMS is required to fund a percentage of the cost of the projects. EVMS' share of the cost is funded through fundraising and the issuance of long-term debt. The restriction on the funds received from the Commonwealth of Virginia is being released over the life of the debt EVMS issued to fund the project, in accordance with the donor stipulations specified within the agreement.

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

(s) Recently Issued Accounting Standards

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance, and requires significantly expanded disclosures about revenue recognition. The core principle of the revenue model is than an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is effective for EVMS as of July 1, 2019. Early adoption is permitted. EVMS is currently evaluating the impact on the consolidated financial statements and the options of adopting using either the retrospective or cumulative effect transition method.

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)*, intended to improve financial reporting about leasing transactions. The new lease standard requires lessees to put most leases on their balance sheets but recognize expenses on their income statements in a manner similar to today's accounting. The guidance also eliminates today's real estate—specific provisions and changes the sale and leaseback accounting model for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for EVMS as of July 1, 2020. Early adoption is permitted. EVMS is currently evaluating the impact of adoption of the new lease standard on its consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-08, *Not-for-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made*, which clarifies whether an entity should account for a grant, or similar transaction, as a contribution or as an exchange transaction. The standard is effective for EVMS as of July 1, 2019. Early adoption is permitted. EVMS is currently evaluating the impact of adoption on the consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, amends, and adds disclosure requirements for fair value measurements. The standard is effective for EVMS as of July 1, 2020. Early adoption is permitted. EVMS is currently evaluating the impact of adoption on the consolidated financial statements.

(t) Recently Adopted Accounting Standard

In August 2016, the FASB issued ASU No. 2016-14, *Not-for-Profit Entities (Topic 958): Presentation of Financial Statements of Not-for-Profit Entities.* The ASU reduces the number of net asset classes presented from three to two: with donor restrictions and without donor restrictions; requires all not-for-profit entities (NFPs) to present expenses by their functional and natural classifications in one location in the financial statements; and requires NFPs to provide quantitative and qualitative information about management of liquid resources and availability of financial assets to meet cash

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

needs within one year of the balance sheet date. EVMS adopted the ASU effective July 1, 2018, and applied the changes retrospectively.

(u) Prior Period Immaterial Correction of Errors

EVMS did not record certain net assets when accounting for its interest in net assets of EVMS Foundation and EVMS did not eliminate certain interdepartmental operating revenues and support and operating expenses in the prior period. These immaterial errors were corrected retrospectively in the periods presented and resulted in an increase in interest in net assets of affiliate of \$29,572,264 in long-term assets and a corresponding increase in net assets with donor restrictions (previously temporarily restricted net assets) as presented on the consolidated balance sheet as of June 30, 2018. The change in interest in net assets of affiliate, which is presented within nonoperating items on the consolidated statement of activities, decreased by \$318,617 for the year ended June 30, 2018. The elimination of certain interdepartmental transfers resulted in a decrease of \$7,685,370 in total operating revenues and support and a corresponding decrease in total operating expenses for the year ended June 30, 2018.

(v) Subsequent Events

EVMS has evaluated subsequent events from the consolidated balance sheet date through October 31, 2019, the date at which the consolidated financial statements were available to be issued, and determined there are no items to disclose.

(3) Cash and Cash Equivalents

Cash and cash equivalents at June 30 are summarized as follows:

| | _ | 2019 | 2018 |
|-----------------|------------|-------------------------|-----------------------|
| EVMS EVMS MG | \$ | 76,813,101 1,132,788 | 42,688,617 755,700 |
| | \$ <u></u> | 77,945,889 | 43,444,317 |

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

(4) Operating Investments and Restricted Cash

(a) Operating investments at June 30 comprised the following:

| | _ | 2019 | 2018 |
|--|-----|--------------|--------------|
| Money market funds | \$ | 1,168,203 | 734,498 |
| Equity securities | | 428,221 | 491,157 |
| Certificates of deposit | | 4,808,603 | 4,513,081 |
| Mutual fund – fixed income | | 4,239,413 | 4,121,280 |
| Corporate debt | | 10,694,778 | 10,384,302 |
| Asset-backed securities | | 326,579 | 346,717 |
| U.S. government securities | | 13,674,468 | 14,295,432 |
| Equity method investment | | 1,295,331 | 133,527 |
| Cash reserve fund | _ | 541,306 | 1,112,041 |
| Total operating investments | | 37,176,902 | 36,132,035 |
| Less amounts available for current obligations | _ | (21,113,202) | (16,577,386) |
| Long-term operating investments | \$_ | 16,063,700 | 19,554,649 |

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

(b) Restricted cash and investments at June 30 comprised the following:

| | | 2019 | 2018 |
|---|----|-------------------------------------|---------------------------------|
| Restricted for parking garage operations – cash Restricted for student loans – money market funds Restricted for cash balance pension plan – mutual funds | \$ | 1,835,445 2,111,541 1,021,160 | 675,772 2,895,847 725,060 |
| Restricted for interest, debt retirement, and construction per trust indentures: General Revenue Refunding Bonds, Series 2001: | | | |
| Interest fund – money market funds Principal fund – money market funds | | | 13,938 702,741 |
| Total Bonds, Series 2001 | _ | | 716,679 |
| General Revenue Refunding Bonds, Series 2002: Interest fund – money market funds Principal fund – money market funds | _ | | 4,936 377,649 |
| Total Bonds, Series 2002 | | | 382,585 |
| General Revenue Bonds, Series 2006: Interest fund – money market funds Principal fund – money market funds | | 15,097 294,728 | 15,897 278,097 |
| Total Bonds, Series 2006 | _ | 309,825 | 293,994 |
| General Revenue Refunding Bonds, Series 2010: Interest fund – money market funds Principal fund – money market funds | _ | 50,180 260,857 | 26,113 251,520 |
| Total Bonds, Series 2010 | _ | 311,037 | 277,633 |
| General Revenue Bonds, Series 2010: Capitalized interest fund – money market funds Interest fund – money market funds Principal fund – money market funds | _ | 30,187 407,175 | 11 19,865 730,981 |
| Total Bonds, Series 2010 | _ | 437,362 | 750,857 |
| General Revenue Bonds, Series 2011: Interest fund – money market funds Principal fund – money market funds | | 29,276 293,107 | 17,420 292,393 |

17

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

| | _ | 2019 | 2018 |
|---|-----|------------------|-----------|
| Capitalized interest fund – money market funds | \$_ | | 1 |
| Total Bonds, Series 2011 | _ | 322,383 | 309,814 |
| General Revenue Bonds, Series 2018: Interest fund – money market funds Capitalized interest fund – money market funds | _ | 2,714 428,716 | |
| Total Bonds, Series 2018 | _ | 431,430 | |
| Total restricted for interest, debt retirement, and construction per trust indentures | _ | 1,812,037 | 2,731,562 |
| Total restricted cash and investments | \$_ | 6,780,183 | 7,028,241 |

(5) Accounts Receivable, Net

At June 30, accounts receivable comprised the following:

| | | 2019 | 2018 |
|---|-----|---------------------------|---------------------------|
| Gross patient accounts receivable Less contractual allowances | \$ | 20,577,219 (6,282,511) | 22,059,942 (6,504,146) |
| Less allowance for doubtful accounts | | (5,469,662) | (5,618,249) |
| Patient accounts receivable, net | _ | 8,825,046 | 9,937,547 |
| Sponsored programs receivables: | | | |
| Grants and contracts – federal | | 5,585,604 | 7,011,521 |
| Grants and contracts – private | | 835,499 | 488,052 |
| Grants and contracts – state | _ | 147,348 | 269,065 |
| Total sponsored programs receivables | | 6,568,451 | 7,768,638 |
| Local hospitals, net | | 5,113,807 | 3,252,807 |
| Parking | | 90,914 | 99,205 |
| U.S. Department of Education | | 843,563 | 1,002,587 |
| Tuition receivable, net | | 2,205,241 | 818,194 |
| Other, net | _ | 892,412 | 732,440 |
| Total accounts receivable, net | \$_ | 24,539,434 | 23,611,418 |

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

The activity in the patient allowance for doubtful accounts is summarized as follows for the years ended June 30:

| | _ | 2019 | 2018 |
|--|-----|--------------|--------------|
| Beginning balance as of July 1 | \$ | 5,618,249 | 4,827,053 |
| Provision for bad debts, net of recoveries | | 16,221,293 | 14,080,968 |
| Less write-offs | _ | (16,369,880) | (13,289,772) |
| Ending balance as of June 30 | \$_ | 5,469,662 | 5,618,249 |

(6) Accounts Receivable from Affiliate

At June 30, 2019 and 2018, accounts receivable from affiliate were due from the EVMS Foundation in the amount of \$382,991 and \$771,962, respectively. This receivable is secured by the EVMS Foundation's investments.

(7) Fair Value Measurements

EVMS uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. EVMS determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

- Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible
 to the reporting entity at the measurement date
- Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability
- Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

The following tables present assets and liabilities that are measured at fair value on a recurring basis at June 30:

| | | Total as of | | | |
|------------------------------------|-----|----------------------------|-------------------------|----------------|--------------|
| | | June 30, 2019 | Level 1 | Level 2 | Level 3 |
| Assets: | | | | | |
| Cash and cash equivalents | \$ | 85,414,421 | 85,414,421 | _ | _ |
| Mutual funds – fixed income | | 4,239,413 | 4,239,413 | _ | _ |
| Mutual funds – large cap | | 1,021,160 | 1,021,160 | _ | _ |
| Equity securities | | 428,221 | 428,221 | _ | _ |
| U.S. government securities | | 13,674,468 | _ | 13,674,468 | _ |
| Corporate debt | | 10,694,778 | _ | 10,694,778 | _ |
| Asset-backed securities | | 326,579 | _ | 326,579 | _ |
| Certificates of deposit | | 4,808,603 | _ | 4,808,603 | _ |
| Beneficial interest in net | | | | | |
| assets of affiliate | _ | 128,081,411 | | | 128,081,411 |
| Total | \$_ | 248,689,054 | 91,103,215 | 29,504,428 | 128,081,411 |
| Liability: | | | | | |
| Interest rate swaps | \$ | (1,591,672) | _ | (1,591,672) | _ |
| | | Total as of | | | |
| | | June 30, 2018 | Level 1 | Level 2 | Level 3 |
| Acceta | | | | | |
| Assets: Cash and cash equivalents | \$ | 51,593,037 | E1 E02 027 | | |
| Mutual funds – fixed income | φ | 4,121,280 | 51,593,037 4,121,280 | _ | _ |
| Mutual funds – large cap | | 725,060 | 725,060 | _ | _ |
| Equity securities | | 491,157 | 491,157 | _ | _ |
| U.S. government securities | | 14,295,432 | 491,107 | 14,295,432 | _ |
| Corporate debt | | 10,384,302 | _ | 10,384,302 | _ |
| Asset-backed securities | | 346,717 | _ | 346,717 | _ |
| Certificates of deposit | | 4,513,081 | _ | 4,513,081 | _ |
| Beneficial interest in net | | 4,515,061 | _ | 4,513,061 | _ |
| assets of affiliate | | | | | |
| assets of anniate | | 105,900,342 | _ | _ | 105,900,342 |
| Total | \$ | 105,900,342 192,370,408 | 56,930,534 | 29,539,532 | 105,900,342 |
| | \$ | | 56,930,534 | 29,539,532 | |

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

The following methods and assumptions were used to estimate the fair value of each class of financial instruments:

- Cash and cash equivalents: Consist of repurchase agreements, cash reserve funds, and short-term money market funds, which are valued at \$1 per share, which is the price the shares trade at in an active market
- Mutual funds: Valued at the daily quoted net asset value of shares held, which is based on the quoted market prices of the underlying assets of the funds
- Equity securities: Valued using quoted prices from the exchanges upon which the securities actively trade
- U.S. government securities, corporate debt, asset-backed securities, and certificates of deposit: Valued based upon proprietary valuation models that may consider market characteristics, such as benchmark yield curves, option-adjusted spreads, credit spreads, estimated default rates, coupon rates, anticipated timing of principal repayments, underlying collateral, and other security features in order to estimate relevant cash flows, which are discounted to fair value
- Beneficial interest in net assets of affiliate: Reported at fair value, based on the value of the underlying assets, which approximates the present value of future income
- Interest rate swaps (note 10): The fair value of the interest rate swaps is determined using pricing
 models that consider assumptions, including time value, interest rates, and yield curves, as well as
 other relevant economic measures.

EVMS' accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2, or Level 3 for the year ended June 30, 2019 or 2018.

(8) Property, Plant, and Equipment, Net

At June 30, property, plant, and equipment consisted of the following:

| | _ | 2019 | 2018 |
|--|----|---------------|---------------|
| Land | \$ | 2,969,342 | 2,992,314 |
| Land improvements | | 9,320,940 | 9,320,940 |
| Buildings and improvements | | 191,961,029 | 187,480,589 |
| Equipment | | 78,003,220 | 75,299,117 |
| Construction in progress | _ | 32,279,521 | 9,834,563 |
| | | 314,534,052 | 284,927,523 |
| Less accumulated depreciation and amortization | _ | (167,828,209) | (159,471,610) |
| Total property, plant, and equipment, net | \$ | 146,705,843 | 125,455,913 |

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

Depreciation and amortization expenses related to property, plant, and equipment for the years ended June 30, 2019 and 2018 were \$9,386,553 and \$10,248,539, respectively.

(9) Lines of Credit

EVMS has a \$10,000,000 unsecured line of credit facility with a bank. Under the terms of the agreement, interest is payable at one-month LIBOR plus 1.50% (3.90% at June 30, 2019). The line of credit was not utilized during the year ended June 30, 2019 and expires on January 9, 2020. EVMS plans to renew the line of credit in fiscal year 2020.

EVMS MG has a \$3,000,000 line of credit facility with a bank, which is subject to semiannual review and expires on May 30, 2020. This facility is collateralized by certain accounts receivable. Interest is payable at the one-month LIBOR plus 1.50% (3.90% at June 30, 2019). No amounts were outstanding under the line of credit at June 30, 2019 or 2018.

(10) Long-Term Debt

At June 30, long-term debt consisted of bonds payable and related interest rate swap agreements as follows:

| | _ | 2019 | 2018 | _ |
|--|-----|-------------|-------------|-----|
| Bonds (property and equipment fund): | | | | |
| General Revenue Refunding Bonds, Series 2001 | \$ | _ | 1,200,000 | |
| General Revenue Refunding Bonds, Series 2002 | | _ | 645,000 | |
| General Revenue Bonds, Series 2006 | | 5,975,000 | 6,450,000 | (A) |
| General Revenue Bonds, Series 2010 | | 10,000,000 | 12,000,000 | (B) |
| General Revenue Refunding Bonds, Series 2010 | | 8,425,000 | 8,855,000 | (C) |
| General Revenue Bonds, Series 2011 | | 8,300,000 | 8,800,000 | (D) |
| General Revenue Bonds, Series 2018 | _ | 2,340,582 | | (E) |
| | | 35,040,582 | 37,950,000 | |
| Interest rate swaps | | 1,591,672 | 363,991 | (F) |
| Less bond issuance costs | | (323,218) | (277,070) | |
| Less current portion | _ | (1,945,000) | (4,500,000) | _ |
| Noncurrent portion | \$_ | 34,364,036 | 33,536,921 | _ |

(A) On June 15, 2006, EVMS issued the Series 2006 General Revenue Bonds. The Series 2006 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by an Eighth Supplemental Indenture of Trust dated June 1, 2006. The Series 2006 Bonds, maturing on November 15, 2028, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed plus accrued interest on November 15, 2009 and each November 15 thereafter through 2028. In addition,

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

the bonds are also subject to optional redemption, as described in the Indentures of Trust mentioned above.

On October 17, 2011, EVMS modified the Series 2006 General Revenue Bonds, in accordance with the Twelfth Supplemental Indenture of Trust, effective November 1, 2011, to reduce the current interest rate payable from 4.00% per annum to 2.95% per annum until the rate reset date, which was also adjusted from June 15, 2021 to November 15, 2021.

Interest is payable semi-annually on each May 15 and November 15 at a rate of 2.95% per annum until the reset date of November 15, 2021. Effective November 15, 2021, the interest rate per annum will reset based on the 10-year average of the 7-year U.S. Treasury bond plus 30 basis points. Mandatory sinking fund payments will be due annually on November 15 as follows:

| Fiscal year maturities | Principal amount | Fiscal year maturities | Principal amount | Fiscal year maturities | Principal amount |
|------------------------------|--|------------------------------|--|------------------------|--------------------------|
| 2020 2021 2022 2023 | \$ 500,000 520,000 540,000 560,000 | 2024 2025 2026 2027 | \$ 580,000 605,000 630,000 650,000 | 2028 2029 | \$ 680,000 710,000 |

(B) On October 29, 2010, EVMS issued the Series 2010 General Revenue Bonds. The Series 2010 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by a Tenth Supplemental Indenture of Trust dated October 1, 2010. The Series 2010 Bonds, maturing on November 15, 2027, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed plus accrued interest on May 15, 2011 and each May 15 and November 15 thereafter through 2027. In addition, the bonds are also subject to optional redemption, as described in the Indentures of Trust mentioned above.

On February 27, 2019, EVMS modified the Series 2010 Bonds, in accordance with the Seventeenth Supplemental Indenture of Trust, dated as of April 1, 2019, to delete the put date, remove the 2010 foundation guarantee, and to modify the floating interest rate from 67% of the sum of one-month LIBOR plus 184 basis points to 79% of the sum of one-month LIBOR plus 85 basis points (2.57% and 2.62% as of June 30, 2019 and 2018, respectively).

Interest is payable semi-annually on each November 15 and May 15. EVMS made early redemption payments of \$750,000 and \$90,000 on the Series 2010 Bonds during the years ended June 30, 2019

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

and 2018, respectively, reducing the principal of the Series 2010 Bonds to \$10,000,000 as of June 30, 2019. Mandatory sinking fund payments will be due annually on November 15 as follows:

| Fiscal year maturities | Principal amount | Fiscal year maturities | Principal amount | Fiscal year maturities | Principal amount |
|------------------------------|---|------------------------------|--|------------------------|------------------|
| 2020 2021 2022 2023 | \$ 500,000 1,250,000 1,250,000 1,250,000 | 2024 2025 2026 2027 | \$ 1,250,000 1,250,000 1,250,000 1,250,000 | 2028 | \$ 750,000 |

(C) On November 15, 2010, EVMS refunded \$10,000,000 of the Series 2008 Bonds by issuing the Series 2010 General Revenue Refunding Bonds. The Series 2010 Refunding Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by an Eleventh Supplemental Indenture of Trust dated November 1, 2010. The Series 2010 Refunding Bonds, maturing on November 15, 2032, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed plus accrued interest on May 15, 2011 and each May 15 and November 15 thereafter through 2032. In addition, the bonds are also subject to optional redemption, as described in the Indentures of Trust mentioned above.

On February 27, 2019, EVMS modified the Series 2010 Refunding Bonds, in accordance with the Seventeenth Supplemental Indenture of Trust, dated as of April 1, 2019, to delete the put date, remove the 2010 foundation guarantee, and to modify the floating interest rate from 67% of the sum of one-month LIBOR plus 169 basis points to 79% of the sum of one-month LIBOR plus 95 basis points (2.65% and 2.52% as of June 30, 2019 and 2018, respectively).

Interest is payable semi-annually on each November 15 and May 15. Mandatory sinking fund payments will be due annually on November 15 as follows:

| Fiscal year maturities | Principal amount | Fiscal year maturities | Principal amount | Fiscal year maturities | Principal amount |
|------------------------|-------------------------|---------------------------|-------------------------|---------------------------|-------------------------|
| 2020 | \$ 445,000 | 2025 | \$ 555,000 | 2030 | \$ 690,000 |
| 2021 | 465,000 | 2026 | 580,000 | 2031 | 720,000 |
| 2022 | 490,000 | 2027 | 605,000 | 2032 | 755,000 |
| 2023 | 510,000 | 2028 | 635,000 | 2033 | 785,000 |
| 2024 | 530,000 | 2029 | 660,000 | | |

(D) On November 17, 2011, EVMS issued the Series 2011 General Revenue Bonds. The Series 2011 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by a Thirteenth Supplemental Indenture of Trust dated November 1, 2011. The Series 2011 Bonds, maturing on November 15, 2032, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

redeemed plus accrued interest on May 15, 2012 and each May 15 and November 15 thereafter through 2032.

On February 27, 2019, EVMS modified the Series 2011 General Revenue Bonds, in accordance with the Seventeenth Supplemental Indenture of Trust, dated as of April 1, 2019, to delete the put date, remove the 2010 foundation guarantee, and to modify the floating interest rate from 65% of the sum of one-month LIBOR plus 170 basis points to 79% of the sum of one-month LIBOR plus 95 basis points (2.65% and 2.45% as of June 30, 2019 and 2018, respectively).

Interest is payable semi-annually on each November 15 and May 15. Mandatory sinking fund payments will be due annually on November 15 as follows:

| Fiscal year maturities | Principal amount | Fiscal year maturities | Principal amount | Fiscal year maturities | Principal amount |
|---------------------------|---------------------|---------------------------|-------------------------|------------------------|-------------------------|
| 2020 \$ | 500,000 | 2025 | \$ 550,000 | 2030 | \$ 650,000 |
| 2021 | 500,000 | 2026 | 550,000 | 2031 | 700,000 |
| 2022 | 500,000 | 2027 | 600,000 | 2032 | 700,000 |
| 2023 | 500,000 | 2028 | 600,000 | 2033 | 750,000 |
| 2024 | 550,000 | 2029 | 650,000 | | |

(E) On December 12, 2018, EVMS issued the Series 2018 General Revenue Bonds. The Series 2018 Bonds are secured by a Master Indenture of Trust dated November 15, 1991 between EVMS and U.S. Bank, as trustee, as amended, and supplemented by a Fourteenth Supplemental Indenture and Master Indenture dated November 1, 2018. The Series 2018 Bonds, maturing November 15, 2038, are subject to mandatory sinking fund redemption by lot at a redemption price of 100% of the principal amount redeemed, plus accrued interest on May 15, 2019 and each May 15 and November 15, thereafter through 2038.

Interest is payable semi-annually on each May 15 and November 15 at a rate of 3.46% per annum. Mandatory sinking fund payments will be due annually on November 15 as follows:

| Fiscal year maturities | Principal amount | Fiscal year maturities | _ | Principal amount | Fiscal year maturities | Principal amount |
|------------------------|------------------|------------------------|----|---------------------|------------------------|-------------------------|
| 2022 \$ | 35,109 | 2028 | \$ | 98,304 | 2034 | \$ 184,906 |
| 2023 | 47,982 | 2029 | | 114,689 | 2035 | 190,757 |
| 2024 | 49,152 | 2030 | | 138,094 | 2036 | 197,779 |
| 2025 | 63,196 | 2031 | | 134,583 | 2037 | 204,801 |
| 2026 | 76,069 | 2032 | | 141,605 | 2038 | 212,993 |
| 2027 | 79,580 | 2033 | | 150,968 | 2039 | 220,015 |

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

(F) EVMS has entered into interest rate swap contracts for its variable rate debt to minimize the effect of changes in LIBOR. The terms of the related interest rate swap contracts are as follows:

The Series 2010 General Revenue Bonds bear interest at 79% of one-month LIBOR plus 85 basis points (2.57% and 2.62% as of June 30, 2019 and 2018, respectively). The related interest rate swap contract has a current notional principal amount of \$10,000,000, under which EVMS pays interest at 3.07% and receives interest at 79% of one-month LIBOR plus 85 basis points. The cumulative unrealized loss of \$466,416 and \$118,411 as of June 30, 2019 and 2018, respectively, from the changes in the swap contract's fair value is included in long-term debt. The swap will expire on November 15, 2027.

The Series 2010 General Revenue Refunding Bonds bear interest at 79% of one-month LIBOR plus 95 basis points (2.65% and 2.52% as of June 30, 2019 and 2018, respectively). The related interest rate swap contract has a current notional principal amount of \$8,425,000, under which EVMS pays interest at 3.28% and receives interest at 79% of one-month LIBOR plus 95 basis points. The cumulative unrealized loss of \$657,762 and \$200,735 as of June 30, 2019 and 2018, respectively, from the changes in the swap contract's fair value is included in long-term debt. The swap will expire on November 15, 2032.

The Series 2011 General Revenue Bonds bear interest at 79% of one-month LIBOR plus 95 basis points (2.65% and 2.45% as of June 30, 2019 and 2018, respectively). The related interest rate swap contract has a current notional principal amount of \$8,300,000, under which EVMS pays interest at 2.99% and receives interest at 79% of one-month LIBOR plus 95 basis points. The cumulative unrealized loss of \$467,494 and \$16,376 as of June 20, 2019 and 2018, respectively, from the changes in the swap contract's fair value are included in long-term debt. The swap will expire on November 15, 2032.

Annual changes in the swap contracts' fair value are included in nonoperating items in the accompanying consolidated statement of activities.

Pursuant to the terms of the Indentures of Trust, EVMS is required to comply with certain covenants regarding payment of bonds, pledging of revenues, the operations of EVMS, insurance, accounting and financial statements, limitations on liens and the incurrence of additional indebtedness, and the sale, lease, or other disposition of assets. EVMS was in compliance with its covenants for the fiscal years ended June 30, 2019 and 2018. The Series 2006 Bonds are equally and ratably secured by an unconditional guaranty of EVMS Foundation and by security interest in revenue granted by EVMS. The Series 2010, Series 2011, and Series 2018 Bonds are equally and ratably secured by security interest in revenue granted by EVMS.

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

Payment requirements on EVMS' bonds payable for the next five fiscal years ending June 30 and thereafter are as follows:

| 2020 | \$ 1,945,000 |
|------------|------------------|
| 2021 | 2,735,000 |
| 2022 | 2,815,109 |
| 2023 | 2,867,982 |
| 2024 | 2,959,152 |
| Thereafter | 21,718,339 |
| | \$ 35,040,582 |

(11) Leases

EVMS has several noncancelable operating leases, primarily for buildings and medical and office equipment, which expire over the next five years. These leases generally contain renewal options for periods ranging from one to five years. Rental expense for operating leases for the years ended June 30, 2019 and 2018 was \$2,647,546 and \$2,690,871, respectively.

Future minimum lease payments under noncancelable operating leases (with initial or remaining lease terms in excess of one year), are as follows:

| Year ending June 30: | | |
|-------------------------|-----|------------|
| 2020 | \$ | 2,389,914 |
| 2021 | | 2,293,004 |
| 2022 | | 2,329,498 |
| 2023 | | 2,012,054 |
| 2024 | | 1,450,278 |
| Thereafter | _ | 946,255 |
| Total minimum operating | | |
| lease payments | \$_ | 11,421,003 |
| | _ | |

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

(12) Grant Deposits

At June 30, grant deposits for sponsored research consisted of the following:

| | _ | 2019 | 2018 |
|--------------------------|----|-----------|-----------|
| Federal grants | \$ | 421,029 | 624,045 |
| State and local grants | | 352,003 | 281,597 |
| Private gifts and grants | | 2,246,260 | 1,727,797 |
| Total grant deposits | \$ | 3,019,292 | 2,633,439 |

Grant deposits represent amounts received for various grants and contracts that have not been expended at June 30, 2019 and 2018. If amounts are not expended per agreement, they will be refunded to the grantors, as required.

(13) Assets Held for Affiliate

Various donors contributed funds to the EVMS Foundation for the purpose of establishing loan funds for EVMS students. EVMS manages the award and subsequent collection of these loans from EVMS students on behalf of the EVMS Foundation. The amount of loan funds held for the EVMS Foundation at June 30, 2019 and 2018 was \$928,199 and \$910,855, respectively.

(14) State Appropriations

EVMS receives state appropriations funds annually. A summary of the programs supported for the years ended June 30 is as follows:

| | 2019 | 2018 |
|---------------------------------------|------------------|--------------|
| Education | \$ 18,708,617 | 17,024,048 |
| Indigent care | 6,158,108 | 6,158,108 |
| Family medicine | 658,597 | 665,164 |
| Medical modeling and simulation | 464,834 | 510,600 |
| Higher education equipment trust fund | 183,101 | 524,429 |
| Capital maintenance reserve | 146,538 | 317,353 |
| Capital projects _ renovations | 2,896,907 | 527,239 |
| Capital projects – new construction | 20,559,541 | _ |
| Virginia Area Health Education Center | 60,620 | 60,620 |
| | \$ 49,836,863 | 25,787,561 |

(15) Functional Expenses by Natural Classification

EVMS allocates its expenses on a functional basis among its various programs and supporting services. Expenses that can be identified with a specific program or supporting service are allocated directly. Other expenses that are common to several functions are allocated using cost allocation methods, including square footage, facility usage, and time and attendance. The expenses allocated include depreciation and

Notes to Consolidated Financial Statements

June 30, 2019
(With summarized financial information as of June 30, 2018)

amortization, salaries and wages, benefits, payroll taxes, professional services, office expenses, information technology, interest, insurance, and other.

Expenses are reported in the consolidated statement of activities in functional categories. Expenses by natural category for the years ended June 30 were as follows:

| | For the year ended June 30, 2019 | | | | | | | | | |
|-------------------------------|----------------------------------|------------------------------|----------------------|------------|------------------|------------------|-----------------------|--------------------|--------------------------------|-------------|
| | | Undergraduate instruction | Graduate instruction | Research | Patient services | Academic support | Institutional support | Auxiliary services | Patient services support | Totals |
| Operating expenses: | | | | | | | | | | |
| Salaries and wages | \$ | 37,661,010 | 21,061,621 | 10,238,417 | 46,743,295 | 6,621,286 | 12,032,933 | 5,027,625 | 3,775,265 | 143,161,452 |
| Fringe benefits | | 7,127,391 | 6,054,170 | 2,015,759 | 7,093,808 | 1,296,477 | 3,210,005 | 659,866 | 968,547 | 28,426,023 |
| Operating supplies | | 1,287,157 | 256,076 | 1,226,660 | 5,654,260 | 1,486,801 | 1,237,859 | 369,067 | 138,813 | 11,656,693 |
| Contractual services | | 46,887,674 | 329,106 | 9,857,606 | 1,213,380 | 716,880 | 4,669,792 | 2,217,709 | 1,021,802 | 66,913,949 |
| General expenses | | 4,641,326 | 1,620,102 | 1,860,349 | 9,357,557 | (156,805) | 2,060,099 | 6,725,213 | 1,527,200 | 27,635,041 |
| Depreciation and amortization | _ | 1,594,130 | 17,734 | 359,069 | 668,040 | | 179,569 | 6,236,069 | 331,942 | 9,386,553 |
| Total operating expenses | \$ | 99,198,688 | 29,338,809 | 25,557,860 | 70,730,340 | 9,964,639 | 23,390,257 | 21,235,549 | 7,763,569 | 287,179,711 |

| | For the year ended June 30, 2018 | | | | | | | | | |
|-------------------------------|----------------------------------|---------------------------|----------------------|------------|------------------|------------------|-----------------------|-----------------------|--------------------------------|-------------|
| | | Undergraduate instruction | Graduate instruction | Research | Patient services | Academic support | Institutional support | Auxiliary services | Patient services support | Totals |
| Operating expenses: | | | | | | | | | | |
| Salaries and wages | \$ | 32,679,176 | 20,671,478 | 10,953,676 | 44,104,474 | 5,586,682 | 10,892,123 | 4,781,900 | 3,213,084 | 132,882,593 |
| Fringe benefits | | 6,065,208 | 5,421,596 | 2,050,452 | 6,944,263 | 1,163,590 | 2,861,200 | 553,672 | 884,732 | 25,944,713 |
| Operating supplies | | 921,236 | 146,415 | 1,355,721 | 5,398,442 | 1,447,423 | 1,034,974 | 245,711 | 181,106 | 10,731,028 |
| Contractual services | | 3,193,707 | 322,288 | 10,181,547 | 2,524,389 | 598,540 | 3,886,696 | 2,352,803 | 404,761 | 23,464,731 |
| General expenses | | 5,180,198 | 1,559,998 | 1,868,321 | 7,551,437 | 89,126 | 1,405,856 | 5,803,709 | 3,188,448 | 26,647,093 |
| Depreciation and amortization | _ | 1,915,690 | 17,805 | 297,673 | 951,075 | | 191,896 | 6,819,751 | 54,649 | 10,248,539 |
| Total operating expenses | \$ | 49,955,215 | 28,139,580 | 26,707,390 | 67,474,080 | 8,885,361 | 20,272,745 | 20,557,546 | 7,926,780 | 229,918,697 |

(16) Retirement Plan

Substantially all of the salaried personnel of EVMS are eligible after specified periods of employment to participate in qualified tax-deferred annuity plans under Sections 403(b) and 401(a) of the IRC. EVMS' contributions to the plans are based on percentages of qualified employee earnings. EVMS contributions to this program were \$5,298,952 and \$5,155,922 for the fiscal years ended June 30, 2019 and 2018, respectively.

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

(17) Commitments and Contingencies

Amounts received and expended by EVMS under various federal and state programs are subject to audit by various federal and state agencies. In the opinion of management, audit adjustments, if any, will not have a significant effect on the consolidated financial position of the School.

EVMS is subject to various legal proceedings and claims, which arise in the ordinary course of its business. Appropriate provision has been made for possible losses, and in the opinion of management, the ultimate resolution of these matters will not have a material adverse effect on the consolidated financial position, results of activities, or liquidity of the School.

(18) Concentrations of Credit Risk

EVMS MG grants credit without collateral to its patients, most of whom are local residents and are insured under third-party payor agreements. The approximate mix of receivables from patients and third-party payors by type of payor, for the years ended June 30, is as follows:

| | 2019 | 2018 |
|--------------------------|-------|-------|
| Self-pay | 32 % | 35 % |
| Medicare | 15 | 15 |
| Medicaid | 7 | 6 |
| HMO (none more than 10%) | 17 | 19 |
| Commercial | 12 | 10 |
| Anthem | 8 | 7 |
| Other | 9 | 8 |
| | 100 % | 100 % |

Notes to Consolidated Financial Statements

June 30, 2019

(With summarized financial information as of June 30, 2018)

(19) Sources of Patient Service Revenue

EVMS MG recognizes patient service revenue associated with services provided to patients who have third-party payor coverage on the basis of established contractual rates for the services rendered. For uninsured patients that do not qualify for charity care, EVMS MG recognizes revenue on the basis of its standard rates for services provided. On the basis of historical experience, a portion of uninsured patients will be unable or unwilling to pay for the services provided. Thus, EVMS MG records a provision for bad debts related to uninsured patients in the period the services are provided. Patient service revenue, net of contractual allowances and discounts recognized in the period from these major payor sources are as follows:

| | _ | 2019 | 2018 |
|--------------------|----|------------|------------|
| Third-party payors | \$ | 60,801,593 | 57,364,873 |
| Self-pay | _ | 12,484,295 | 12,465,980 |
| Total all payors | \$ | 73,285,888 | 69,830,853 |

(20) Liquidity and Availability

Financial assets available for general expenditure within one year of the balance sheet date are as follows:

| Total assets | \$ 432,486,838 |
|--|-------------------|
| Less: | |
| Restricted cash and investments | 6,780,183 |
| Property, plant, and equipment, net | 146,705,843 |
| Noncurrent operating investments | 16,063,700 |
| Notes receivable from students | 3,746,182 |
| Interest in net assets of affiliate | 128,081,411 |
| Other long-term assets | 3,892,971 |
| Financial assets available within one year | \$ 127,216,548 |

EVMS manages its financial assets to be available as its operating expenditures, liabilities, and other obligations come due. Although the noncurrent investments disclosed in the table above are intended to be held long-term, EVMS could utilize those investments within the next year if deemed necessary. As described in note 9, EVMS has available lines of credit in the amounts of \$10 million and \$3 million, with no amounts outstanding at June 30, 2019. The lines of credit expire in January 2020 and May 2020, respectively. EVMS plans to renew in fiscal year 2020.

Schedule of Expenditures of Federal Awards

Year ended June 30, 2019

| Federal grantor agency/program title | Pass-through entity | Pass-through entity identifying number | CFDA/Grant number | Passed through to subrecipients | Total federal expenditures |
|--|---|---|--------------------------------------|---------------------------------------|--|
| Student financial assistance cluster: | r ass-unough entity | identifying number | Humber | Subrecipients | expenditures |
| Department of Education: Cash assistance – Federal Perkins Loan Program (note 4) Noncash assistance – Federal Direct Student Loans Program (note 2) | | | 84.038 84.268 | \$ <u> </u> | 2,596,236 49,296,100 |
| Department of Health and Human Services: Health Professions Student Loans (note 4): Primary Care Loans Loans for Disadvantaged Students | | | 93.342 93.342 | | 781,688 796,903 |
| Subtotal 93.342 | | | | | 1,578,591 |
| Total student financial assistance cluster | | | | | 53,470,927 |
| Research and development cluster: Department of Defense: Department of the Army – Military Medical Research and Development | | | 12.420 | 2,871 | 210,480 |
| Department of Housing and Urban Development: Office of Lead Hazard Control and Healthy Homes - Healthy Homes Technical Studies Grants | | | 14.906 | _ | 183,052 |
| National Aeronautics and Space Administration: Exploration | | | 43.003 | _ | 373,292 |
| Exploration | University of California Irvine | 3210920618 | 43.003 | | 257,836 |
| Subtotal 43.003 | | | | | 631,128 |
| National Science Foundation: Engineering Grants | Norfolk State University | F1040102 | 47.041 | _ | 11,805 |
| Department of Health and Human Services: National Institutes of Health – Family Smoking Prevention and Tobacco Control Act Regulatory Research National Institutes of Health – Family Smoking Prevention and Tobacco Control Act | | | 93.077 | 10,975 | 13,561 |
| Regulatory Research | Virginia Commonwealth University | FP00008477_SA007 | 93.077 | | 2,316 |
| Subtotal 93.077 | | | | 10,975 | 15,877 |
| National Institutes of Health – National Center on Sleep Disorders Research National Institutes of Health – Mental Health Research Grants | Children's Hospital of Philadelphia | 3210920618 | 93.233 93.242 | 650,930 | 73,511 1,081,319 |
| National Institutes of Health – Drug Abuse and Addiction Research Programs National Institutes of Health – Drug Abuse and Addiction Research Programs National Institutes of Health – Drug Abuse and Addiction Research Programs National Institutes of Health – Drug Abuse and Addiction Research Programs | Old Dominion Research Foundation Washington University - St. Louis The Regents of the University | 16-209-100581-010 WU-17-186 A18-2681-S002 | 93.279 93.279 93.279 93.279 | 11,067 — — — | 65,245 28,298 15,208 11,846 |
| Subtotal 93.279 | | | | 11,067 | 120,597 |
| National Institutes of Health – Minority Health and Health Disparities Research National Institutes of Health – Minority Health and Health Disparities Research | American College of Surgeons The Brigham & Women's Hospital | 24292GP001EVMS 119569 | 93.307 93.307 | | 35,029 9,138 |
| Subtotal 93.307 | | | | | 44,167 |
| National Institutes of Health – Cancer Detection and Diagnosis Research National Institutes of Health – Cancer Treatment Research | | | 93.394 93.395 | 172,194 — | 455,710 24,536 |
| National Institutes of Health - Cardiovascular Diseases Research National Institutes of Health - Cardiovascular Diseases Research National Institutes of Health - Cardiovascular Diseases Research | University of Arizona Rutgers University | 493168 8253 | 93.837 93.837 93.837 | 134,769 — — | 764,368 94,372 170,577 |
| Subtotal 93.837 | | | | 134,769 | 1,029,317 |
| National Institutes of Health – Lung Diseases Research National Institutes of Health – Blood Diseases and Resources Research National Institutes of Health – Arthritis, Musculoskeletal and Skin Diseases Research National Institutes of Health – Diabetes, Digestive, and Kidney Diseases Extramural Research | Indiana University | IN4689693-EVMS | 93.838 93.839 93.846 93.847 | _ _ _ | 214,096 169,681 152,672 110,603 |
| National Institutes of Health – Extramural Research Programs in the: Neurosciences and Neurological Disorders Neurosciences and Neurological Disorders Neurosciences and Neurological Disorders | Massachusetts General Hospital Albert Einstein College of Medicine Virginia Commonwealth University | PS#230754 311302 FP00007840_SA002 | 93.853 93.853 93.853 | | 57,907 31,162 51,164 |
| Subtotal 93.853 | | | | | 140,233 |

Schedule of Expenditures of Federal Awards

Year ended June 30, 2019

| Federal grantor agency/program title | Pass-through entity | Pass-through entity identifying number | CFDA/Grant number | Passed through to subrecipients | Total federal expenditures |
|--|---|---|--|--|---|
| National Institutes of Health – Allergy, Immunology and Transplantation Research National Institutes of Health – Allergy, Immunology and Transplantation Research National Institutes of Health – Allergy, Immunology and Transplantation Research National Institutes of Health – Allergy, Immunology and Transplantation Research National Institutes of Health – Allergy, Immunology and Transplantation Research National Institutes of Health – Allergy, Immunology and Transplantation Research | Johns Hopkins University Johns Hopkins University Northwestern University Northwestern University Childrens Specialty Group | 2003925392 2002351791/Al13127-01 60040631EVMS 60040628EVMS 270781 | 93.855 93.855 93.855 93.855 93.855 93.855 | \$ 83,529 — — — — | 742,690 24,873 37,034 104,787 220,820 11,436 |
| Subtotal 93.855 | Gillarens openially Group | 270701 | 30.000 | 83,529 | 1,141,640 |
| National Institutes of Health – Biomedical Research and Research Training | The University of Richmond | 27442S | 93.859 | | 28,572 |
| National Institutes of Health – Child Health and Human Development Extramural Research National Institutes of Health – Child Health and Human Development Extramural Research National Institutes of Health – Child Health and Human Development Extramural Research National Institutes of Health – Child Health and Human Development Extramural Research National Institutes of Health – Child Health and Human Development Extramural Research National Institutes of Health – Child Health and Human Development Extramural Research National Institutes of Health – Child Health and Human Development Extramural Research | University of Kentucky University of Pennsylvania University of Maryland Family Health International Social & Scientific Systems Oregon Health & Science University | 32600000306-16-106 564595 1302 /1903086 / SR00004938 104083/0910.0001/100293.001003 PHR-SSS-S-16-005289 1009136_EVMS | 93.865 93.865 93.865 93.865 93.865 93.865 93.865 | 356,643 — — — — — — | 701,796 434,274 73,070 192,564 11,911 54,799 25,491 |
| Subtotal 93.865 | | | | 356,643 | 1,493,905 |
| National Institutes of Health – Aging Research National Institutes of Health – Medical Library Assistance | Artann Laboratories, Inc. University of Maryland | VTI09 5UG4LM012340-03 | 93.866 93.879 | _ | 21,803 7,916 |
| Centers for Disease Control and Prevention – Human Immunodeficiency Virus (HIV) Acquired Immunodeficiency Virus Syndrome (AIDS) Surveillance | Commonwealth of Virginia, Department of Health | EVMSSUR611GY18 | 93.944 | _ | 244,872 |
| Centers for Disease Control and Prevention – Assistance Programs for Chronic Disease Prevention and Control | Commonwealth of Virginia, Department of Health | 709P632494-1 | 93.945 | _ | 347 |
| Centers for Disease Control and Prevention – ESB - Monitoring Juvenile Onset Recurrent Respiratory Papillomatosis | | | 200-2014-59074 | _ | 219,335 |
| Centers for Disease Control and Prevention – PPF 2016 Immunization Grants - JORRP - Financed Solely by 2016 Prevention and Public Health Funds (PPHF) Centers for Disease Control and Prevention – PPF 2016 Immunization Grants - JORRP - Financed Solely | | | 200-2016-91449 | 75,575 | 76,881 |
| by 2016 Prevention and Public Health Funds (PPHF) | | | 200-2016-91451 | 20,381 | 47,217 |
| National Institute of Child Health and Human Development – Contraceptive Clinical Trials | | | 93.HHSN2752013000191 | 93,446 | 578,953 |
| U.S. Agency for International Development: Foreign Assistance for Programs Overseas – Prh/Rtu-Silcs & Tfv/Conrad AID-OAA-A-10-00068 Foreign Assistance for Programs Overseas – App for Aad 936-3090 AID-OAA-A-14-00010 Foreign Assistance for Programs Overseas – App for Aad 936-3090 AID-OAA-A-14-00011 Foreign Assistance for Programs Overseas – App for Aad 936-8900-M AID-OAA-A-15-00033 Foreign Assistance for Programs Overseas – App for Aad 936-3090-M AID-OAA-A-17-00014 | | | 98.001 98.001 98.001 98.001 98.001 | 321,381 375,574 1,136,683 (11,016) 360,444 | 2,133,358 3,256,779 3,266,395 693,791 1,430,227 |
| Subtotal 98.001 | | | | 2,183,066 | 10,780,550 |
| Total research and development cluster | | | | 3,795,446 | 19,310,775 |
| Highway safety cluster: Department of Transportation: National Highway Traffic Safety Administration – State and Community Highway Safety National Highway Traffic Safety Administration – National Priority Safety Programs | Commonwealth of Virginia, DMV Commonwealth of Virginia, DMV | FOP-2019-59102-9102 FM2PE-2018-58059-8059 | 20.600 20.616 | Ξ | 79,984 54,883 |
| Total highway safety cluster | Commonwealth of Virginia, DWV | . INIZI E 2010 00000 0003 | 20.010 | | 134,867 |
| ē | | | | | |

Schedule of Expenditures of Federal Awards

Year ended June 30, 2019

| Federal grantor agency/program title | Pass-through entity | Pass-through entity identifying number | CFDA/Grant number | Passed through to subrecipients | Total federal expenditures |
|--|--|---|----------------------------|---------------------------------------|-----------------------------|
| Other grant programs: Department of Defense: U.S. Army Medical Command – Telemedicine and Advanced Technology Research Center U.S. Army Medical Command – Telemedicine and Advanced Technology Research Center | | | 5056215365 5063266200 | \$ <u> </u> | 22,566 80,980 |
| Department of Health and Human Services: Health Resources and Services Administration – Area Health Education Centers Point of Service Maintenance and Enhancement Awards Health Resources and Services Administration – Advanced Education Nursing Grant Program Health Resources and Services Administration – Grants for Primary Care Training and Enhancement | Virginia Health Workforce Development Authority Old Dominion University Research Foundation | U77HP26289-05-01 & U77HP26289-06-00 18-141-100670-010 & 18-313-10067-020 | 93.107 93.247 93.884 | | 72,016 32,789 446,302 |
| Centers for Disease Control and Prevention – Cancer Prevention and Control Programs for State, Territorial and Tribal Organizations | Commonwealth of Virginia Department of Health | 709L332203 & 709SA832719 | 93.898 | _ | 382,978 |
| Health Resources and Services Administration – HIV Emergency Relief Project Grants | City of Norfolk | 26462-A-G | 93.914 | 688,537 | 1,183,383 |
| Health Resources and Services Administration – HIV Care Formula Grants | Commonwealth of Virginia Department of Health | EVMC31ID811GY18 & EVMC31ID811GY19 | 93.917 | 335,144 | 438,343 |
| Health Resources and Services Administration – Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease Health Resources and Services Administration – Healthy Start Initiative | Commonwealth of Virginia Department of Health | 705V0532406 | 93.918 93.926 | 326,679 — | 361,368 318,405 |
| Centers for Disease Control and Prevention – CDC's Collaboration with Academia to Strengthen Public Health | Association of American Medical College | GT-32016-01-18 | 93.967 | _ | 1,150 |
| Health Resources and Services Administration – Geriatric Education Centers | Virginia Commonwealth University | PT111971-SC106960 | 93.969 | | 93,638 |
| Total other grant programs | | | | 1,421,190 | 3,433,918 |
| Total federal awards, including noncash programs | | | | \$ 5,216,636 | 76,350,487 |

See accompanying notes to schedule of expenditures of federal awards.

Notes to Schedule of Expenditures of Federal Awards Year ended June 30, 2019

(1) Summary of Significant Accounting Policies

(a) Federal Awards

The accompanying Schedule of Expenditures of Federal Awards (the Schedule) presents the activity of all federal awards programs of Eastern Virginia Medical School and Affiliated Organization (EVMS) for the year ended June 30, 2019. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, the amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements. All federal awards received directly and indirectly from federal agencies are included in the Schedule. Although EVMS is required to match certain grants, as defined in the grants, no such matching has been included in the Schedule.

(b) Basis of Accounting

The accompanying Schedule is presented using the accrual basis of accounting and is based on EVMS' policy of recording expenditures for a grant in the year incurred. In certain instances, refunds may be received by EVMS, which are not anticipated. Any refunds in excess of current year expenditures result in negative expenditures in the current year and are returned to the federal government. Negative amounts may also represent adjustments or credits to amounts reported as expenditures in prior years. Expenditures for federal student financial assistance programs are recognized as incurred.

Expenditures for other federal awards are recognized as incurred using cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement.

(c) Indirect Cost Rate

EVMS has elected not to use the 10% de minimis indirect cost rate allowed under the Uniform Guidance.

(2) Federal Direct Student Loans Program

During the year ended June 30, 2019, EVMS processed \$49,296,100 of new loans under the Federal Direct Student Loans Program (CFDA No. 84.268), which includes the Federal Unsubsidized Stafford Loan Program and the Federal Direct PLUS Loan Program.

EVMS is responsible only for the performance of certain administrative duties with respect to the Federal Direct Student Loans Program; accordingly, these loans are not included in its consolidated financial statements. It is not practicable to determine the balance of loans outstanding to students and former students of EVMS under the programs as of June 30, 2019.

Notes to Schedule of Expenditures of Federal Awards Year ended June 30, 2019

(3) Relationship to the Consolidated Financial Statements

The 2019 federal award expenditures and disbursements are reported in the consolidated financial statements of EVMS as of and for the year ended June 30, 2019 as follows:

| | Net assets without donor restrictions | | Net assets with donor restrictions (loans disbursed) |
|---------------------------------------|---------------------------------------|------------|---|
| Student financial assistance programs | \$ | _ | 194,608 |
| Research and development programs | 1 | 9,310,775 | _ |
| Highway safety programs | | 134,867 | _ |
| Other grants and contracts | | 3,433,918 | |
| | \$2 | 22,879,560 | 194,608 |

(4) Federal Perkins Loan Program and Health Professions Student Loans

The Federal Perkins Loan Program (FPL) and Health Professions Student Loans (HPSL) are administered directly by EVMS, and the balances and transactions relating to these programs are included in EVMS' consolidated financial statements. Loans outstanding at the beginning of the year, loans made during the year, and program administration costs are included in the federal expenditures presented in the Schedule. The balances of loans outstanding under these programs at June 30, 2019 were:

| FPL | \$ 1,922,669 |
|----------------------------------|-----------------|
| HPSL: | |
| Primary care loans | 550,145 |
| Loans for disadvantaged students | 727,465 |
| | \$ 3,200,279 |

Under the FPL program, EVMS made no loans and received no federal capital contributions during the year ended June 30, 2019.

Loans of \$0 and \$194,608 were made by EVMS during the year ended June 30, 2019 for primary care loans and loans for disadvantaged students, respectively. Federal capital contributions of \$175,147 were received in HPSL programs during the year ended June 30, 2019.



KPMG LLP Suite 1900 440 Monticello Avenue Norfolk, VA 23510

Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

The Board of Visitors
Eastern Virginia Medical School:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Eastern Virginia Medical School and Affiliated Organization (EVMS), which comprise the consolidated balance sheet as of June 30, 2019, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 31, 2019, which included an emphasis of matter paragraph indicating EVMS adopted Financial Accounting Standards Board Accounting Standards Update No. 2016-14, *Not-for-Profit Entities* (*Topic 958*): *Presentation of Financial Statements of Not-for-Profit Entities*, during the year ended June 30, 2019. Our opinion is not modified with respect to this matter.

Internal Control over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered EVMS' internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of EVMS' internal control. Accordingly, we do not express an opinion on the effectiveness of EVMS' internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect, and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's consolidated financial statements will not be prevented, or detected, and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may not have been identified. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. We did identify certain deficiencies in internal control, described below as items 2019-01 and 2019-02, that we consider to be significant deficiencies.



2019-01 - Beneficial Interest in Net Assets of Affiliate

During our audit procedures performed over EVMS' beneficial interest in the net assets of its affiliate, we noted that EVMS excluded certain net assets of its affiliate from its recorded interest which resulted in an understatement of the net assets. We recommend that EVMS implement internal controls to regularly review its accounting policies and procedures related to its beneficial interest in net assets of affiliate to ensure that amounts are properly recorded.

Management Response

Management has reviewed the accounting standards related to beneficial interest in net assets of affiliates and the treatment recommended compared to the method and assumptions previously applied. EVMS has implemented the new methodology and will continue to monitor going forward.

2019-02 - Interdepartmental Eliminations

During our audit procedures performed over financial reporting, we identified certain interdepartmental transactions that were not eliminated in the consolidated financial statements. We recommend that EVMS implement internal controls to ensure that all interdepartmental transactions are eliminated as part of the year-end financial reporting process.

Management Response

Management agrees with the recommendation to improve the process over eliminating certain interdivisional transactions. Not eliminating the interdepartmental transactions did not impact the operating results of EVMS but did overstate revenue and expenses and therefore this will be adjusted going forward.

EVMS' responses to the findings identified in our audit are described previously. EVMS' responses were not subjected to the auditing procedures applied in the audit of the consolidated financial statements and, accordingly, we express no opinion on the responses.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether EVMS' consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of EVMS' internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering EVMS' internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Norfolk, Virginia October 31, 2019



KPMG LLP Suite 1900 440 Monticello Avenue Norfolk, VA 23510

Independent Auditors' Report on Compliance for Each Major Federal Program; Report on Internal Control over Compliance; and Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

The Board of Visitors
Eastern Virginia Medical School:

Report on Compliance for Each Major Federal Program

We have audited Eastern Virginia Medical School and Affiliated Organization's (EVMS) compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of EVMS' major federal programs for the year ended June 30, 2019. EVMS' major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of EVMS' major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about EVMS' compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of EVMS' compliance.

Opinion on Each Major Federal Program

In our opinion, Eastern Virginia Medical School and Affiliated Organization complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2019.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as item 2019-03. Our opinion on each major federal program is not modified with respect to this matter.



EVMS' response to the noncompliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. EVMS is also responsible for preparing a corrective action plan to address the audit finding included in our auditors' report. EVMS' response and corrective action plan were not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response or the corrective action plan.

Report on Internal Control over Compliance

Management of EVMS is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered EVMS' internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of EVMS' internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, we did identify a certain deficiency in internal control over compliance, described in the accompanying schedule of findings and questioned costs as item 2019-03, that we consider to be a significant deficiency.

EVMS' response to the internal control over compliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. EVMS is also responsible for preparing a corrective action plan to address each audit finding included in our auditors' report. EVMS' response and corrective action plan were not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response or the corrective action plan.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the consolidated financial statements of EVMS as of and for the year ended June 30, 2019, and have issued our report thereon dated October 31, 2019, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the consolidated financial statements as a whole.



Norfolk, Virginia March 11, 2020

Schedule of Findings and Questioned Costs Year ended June 30, 2019

(1) Summary of Auditors' Results

- (a) Type of report issued on whether the financial statements were prepared in accordance with generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
 - Material weaknesses: No
 - Significant deficiencies: Yes 2019-01: Beneficial Interest in Net Assets of Affiliate and 2019-02: Interdepartmental Eliminations
- (c) Noncompliance material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major programs disclosed by the audit:
 - Material weaknesses: No
 - Significant deficiencies: Yes 2019-03: Enrollment Reporting
- (e) Type of report issued on compliance for major programs: Unmodified
- (f) Audit findings that are required to be reported in accordance with 2 CFR 200.516(a): **Yes 2019-03:** *Enrollment Reporting*
- (g) Major program: Student Financial Assistance Program Cluster
- (h) Dollar threshold used to distinguish between Type A and Type B programs: \$2,290,515
- (i) Auditee qualified as a low-risk auditee: Yes

(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with Government Auditing Standards

2019-01: Beneficial Interest in Net Assets of Affiliate

Criteria or Requirement

In accordance with FASB ASC Subtopic 958-20, *Financially Interrelated Entities*, if a beneficiary and a recipient entity are financially interrelated entities, the beneficiary shall recognized its interest in the net assets of the recipient entity.

Condition Found

During our audit procedures performed over EVMS' beneficial interest in the net assets of its affiliate, we noted that EVMS excluded certain net assets of its affiliate from its recorded interest which resulted in an understatement of the net assets in the amount of \$9,137,652 as of June 30, 2019.

Schedule of Findings and Questioned Costs
Year ended June 30, 2019

Possible Cause and Effect

EVMS did not have an internal control process appropriately designed to monitor the recording of its beneficial interest against existing authoritative guidance.

Questioned Costs

There are no questioned costs associated with this finding.

Sampling

The sample was not intended to be, and was not, a statistically valid sample.

Identification of Repeat Finding

The finding was not reported in the prior year's audit.

Recommendation

We recommend that EVMS implement internal controls to regularly review its accounting policies and procedures related to its beneficial interest in net assets of affiliate to ensure that amounts are properly recorded.

Views of Responsible Officials

Management has reviewed the accounting standards related to beneficial interest in net assets of affiliates and the treatment recommended compared to the method and assumptions previously applied. EVMS has implemented the new methodology and will continue to monitor going forward.

2019-02: Interdepartmental Eliminations

Criteria or Requirement

In accordance with FASB ASC Topic 810, *Consolidation*, intra-entity balances and transactions shall be eliminated. This includes intra-entity open account balances, security holdings, sales and purchases, interest, dividends, and so forth. As consolidated financial statements are based on the assumption that they represent the financial position and operating results of a single economic entity, such statements shall not include gain or loss transactions among the entities in the consolidated group. Accordingly, any intra-entity profit or loss on assets remaining within the consolidated group shall be eliminated; the concept usually applied for this purpose is gross profit or loss.

Condition Found

During our audit procedures performed over financial reporting, we identified certain interdepartmental transactions that were not eliminated in the consolidated financial statements. The factual misstatement aggregated to an overstatement of operating revenues and corresponding overstatement of operating expenses in the amounts of \$8,060,454 for the year ended June 30, 2019.

Schedule of Findings and Questioned Costs
Year ended June 30, 2019

Possible Cause and Effect

EVMS had processes in place to track, record, and monitor interdepartmental activity. Management did not have internal controls implemented to ensure interdepartmental transactions were eliminated during the preparation of the consolidated financial statements as part of the year-end financial reporting process.

Questioned Costs

There are no questioned costs associated with this finding.

Sampling

The sample was not intended to be, and was not, a statistically valid sample.

Identification of Repeat Finding

The finding was not reported in the prior year's audit.

Recommendation

We recommend that EVMS implement internal controls to ensure that all interdepartmental transactions are eliminated as part of the year-end financial reporting process.

Views of Responsible Officials

Management agrees with the recommendation to improve the process over eliminating certain interdivisional transactions. Not eliminating the interdepartmental transactions did not impact the operating results of EVMS but did overstate revenue and expenses and therefore this will be adjusted going forward.

(3) Findings and Questioned Costs Related to Federal Awards

2019-03: Enrollment Reporting

Federal Program – Student Financial Assistance Cluster (CFDA No. 84.268)

Federal Agency – U.S. Department of Education

Federal Award Number - P268K196216

Federal Award Year - July 1, 2018 to June 30, 2019

Criteria or Requirement

In accordance with 34 CFR 685.309, enrollment information must be reported to the Secretary within 30 days whenever attendance changes for students, unless a roster will be submitted within 60 days. These changes include reductions or increases in attendance levels, withdrawals, graduations, or approved leaves-of-absence.

Schedule of Findings and Questioned Costs
Year ended June 30, 2019

Condition Found

Enrollment information was not reported to the National Student Loan Data System (NSLDS) within 60 days after the effective date of the change in status for 10 students out of a sample of 25 students.

Possible Cause and Effect

EVMS' system of internal controls over the review of the enrollment status changes and the method for which the changes are submitted to the NSLDS did not operate at a level of precision that would prevent or detect untimely reporting.

Questioned Costs

There are no questioned costs associated with this finding.

Sampling

The sample was not intended to be, and was not, a statistically valid sample.

Identification of Repeat Finding

The finding was not reported in the prior year's audit.

Recommendation

We recommend that EVMS strengthen its processes and controls around enrollment reporting to ensure timely submission of enrollment information.

Views of Responsible Officials

EVMS agrees with this finding and recommendation. EVMS has developed controls around the timeliness of enrollment reporting as indicated in our Corrective Action Plan. EVMS utilizes the National Student Clearinghouse (the Clearinghouse) to submit information to the National Student Loan Database System (NSLDS).

Nine of the instances related to timeliness were due to turnover in the position responsible for enrollment reporting. EVMS submitted the Degree Verification to the Clearinghouse to separate students that had graduated in May 2019 but did not submit a final roster in June 2019. The employee thought the Degree Verification satisfied the NSLDS enrollment reporting requirements. Degree Verification is a separate process from enrollment reporting and therefore it did not initiate a status change in NSLDS.

One of the instances related to timeliness was due to an error in the data share download between the registration system, Vizual Zen, and Oracle, the system of record. The student's registration details did not properly loan into Oracle and were therefore left off the roster report submitted to the NSLDS.



Finding, Response & Corrective Action Plan Year ended June 30, 2019

Finding 2019-01: Beneficial Interest in Net Assets of Affiliate

During our audit procedures performed over EVMS' beneficial interest in the net assets of its affiliate, we noted that EVMS excluded certain net assets of its affiliate from its recorded interest which resulted in an understatement of the net assets.

Recommendation

We recommend that EVMS implement internal controls to regularly review its accounting policies and procedures related to its beneficial interest in net assets of affiliate to ensure that amounts are properly recorded.

Views of Responsible Officials

Management has reviewed the accounting standards related to beneficial interest in net assets of affiliates and the treatment recommended compared to the method and assumptions previously applied. EVMS has implemented the new methodology and will continue to monitor going forward.

Finding 2019-02: Interdivisional Eliminations

During our audit procedures performed over financial reporting, we identified certain interdepartmental transactions that were not eliminated in the consolidated financial statements.

Recommendation

We recommend that EVMS implement internal controls to ensure that all interdepartmental transactions are eliminated as part of the year-end financial reporting process.

Views of Responsible Officials

Management agrees with the recommendation to improve the process over eliminating certain interdivisional transactions. Not eliminating the interdepartmental transactions did not impact the operating results of EVMS but did overstate revenue and expenses and therefore this will be adjusted going forward.

Finding 2019-03: Special Tests and Provisions: Enrollment Reporting

Criteria or Requirement

In accordance with 34 CFR 685.309, enrollment information must be reported within 30 days whenever attendance changes for students, unless a roster will be submitted within 60 days.

Financial Services

These changes include reductions or increases in attendance levels, withdrawals, graduations, or approved leaves-of-absence.

Condition Found

Enrollment information was not reported to the National Student Loan Data System (NSLDS) within 60 days after the effective date of the change in status for ten students out of a sample of 25 students.

Possible Cause and Effect

EVMS' system of internal controls over the review of the enrollment status changes and the method for which the changes are submitted to the NSLDS did not operate at a level of precision that would prevent or detect untimely reporting.

Recommendations

We recommend that EVMS strengthen its processes and controls around enrollment reporting to ensure timely submission of enrollment information.

Views of Responsible Officials

EVMS agrees with this finding and recommendation. EVMS has developed controls around the timeliness of enrollment reporting as indicated in our Corrective Action Plan. EVMS utilizes the National Student Clearinghouse (the Clearinghouse) to submit information to the National Student Loan Database System (NSLDS).

Nine of the instances related to timeliness were due to turnover in the position responsible for enrollment reporting. EVMS submitted the Degree Verification to the Clearinghouse to separate students that had graduated in May 2019 but did not submit a final roster in June 2019. The employee thought the Degree Verification satisfied the NSLDS enrollment reporting requirements. Degree Verification is a separate process from enrollment reporting and therefore it did not initiate a status change in NSLDS.

One of the instances related to timeliness was due to an error in the data share download between the registration system, Vizual Zen, and Oracle, the system of record. The student's registration details did not properly load into Oracle and were therefore left off of the roster report submitted to the NSLDS.

Corrective Action Plan

Beneficial Interest in Net Assets of Affiliate

EVMS will apply the new methodology to analyze all net assets of affiliate organizations when recording EVMS' interest in that organization on the financial statements. EVMS will examine any changes in the reporting requirements each fiscal year and will update our processes when applicable. The anticipated completion date of this procedure is June 30, 2020.

The contact person for this finding is Victoria Dean, Controller

Interdivisional Eliminations

EVMS has implemented a new process to review and reconcile interdivisional revenues and expenses each month. Most interdivisional revenues and expenses will be eliminated on a monthly basis with a final adjustment at fiscal year-end. The anticipated completion date of this procedure is February 7, 2020.

The contact person for this finding is Victoria Dean, Controller.

Timely Submission of Enrollment Data

EVMS will continue to send the Degree Verification to the Clearinghouse and will implement a process to send a final roster of graduates only enrollment file within a month following graduation to properly separate graduated students in NSLDS. The anticipated completion date of this procedure is July 29, 2019.

EVMS is implementing a new student information system which will eliminate the issue between the Vizual Zen and Oracle because both functions will take place in the same system. Until this system is fully implemented, EVMS has created a reconciliation process to compare the registration in Vizual Zen to the registration in Oracle each term. The Registrar will correct any discrepancies in Oracle to ensure all students are included in the roster reporting. The anticipated completion date of this procedure January 28, 2020.

The contact person for this finding is David Golay, Registrar.



Eastern Virginia Medical School Fiscal Year 2019 Prior Audit Findings

Finding 2018-001: Subrecipient Monitoring

Corrective action was taken and findings #2018-001 was corrected in fiscal year 2019.

EVMS updated its standard subaward agreement template to include the required information for subrecipients receiving an award after December 26, 2014, when 2 CFR 200 went into effect. EVMS has not, however, updated the subaward agreements utilized for U.S. Agency for International Development (USAID) subawards because those agreements contained USAID specific terms and conditions. EVMS has since standardized all of its USAID subaward agreements to clearly identify the award as a subaward and provide all of the required award information to the subrecipients as required under 2 CFR 200.331. Additionally, EVMS has emailed this information to all existing subaward recipients.